Patents Assigned to The New York Blood Center, Inc.
  • Patent number: 10938885
    Abstract: A system, method, and apparatus for transferring blood donation files are disclosed. An example system includes a collection device located at a blood donation site and a collection server located in a remote location. The example collection device is configured to store blood donation information from blood donors within a blood donation batch file located at a designated directory of a memory, and store metadata related to the blood donation information to the blood donation batch file. The example collection device also transmits the blood donation batch file to a registered user device. The example collection server is configured to determine the registered user device is available via a network connection. Responsive to determining the user device is connected, the collection server acquires the blood donation batch file from the user device and aggregates the blood donation batch file with blood donation batch files received from other registered user devices.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: March 2, 2021
    Assignee: New York Blood Center, Inc.
    Inventor: Sabyasachi Sarkar
  • Patent number: 10869856
    Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: December 22, 2020
    Assignees: New York Blood Center, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • Patent number: 10612000
    Abstract: The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: April 7, 2020
    Assignee: New York Blood Center, Inc.
    Inventors: Beth H. Shaz, Christopher D. Hillyer
  • Patent number: 10576059
    Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: March 3, 2020
    Assignees: New York Blood Center, Inc., The United States of America, as Represented by the Secretary, Department of Human Services
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • Patent number: 10413527
    Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: September 17, 2019
    Assignees: New York Blood Center, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • Patent number: 10385317
    Abstract: The disclosure provides methods of making a red blood cell, plasma, and platelet products having a uniform dose and volume. The method comprises pooling a plurality of blood units, leukoreducing the blood and inactivating any pathogen contained therein. Plasma, RBCs, and platelets are then divided into uniform dose and volume units which have an extended shelf life.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: August 20, 2019
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventors: Beth Shaz, Christopher D. Hillyer
  • Patent number: 10137107
    Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: November 27, 2018
    Assignees: New York Blood Center, Inc., National Institutes of Health
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • Patent number: 9982230
    Abstract: The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 29, 2018
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventors: Beth H. Shaz, Christopher D. Hillyer
  • Patent number: 9943589
    Abstract: Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: April 17, 2018
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventors: Shibo Jiang, Lanying Du
  • Patent number: 9889194
    Abstract: Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: February 13, 2018
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Lanying Du, Yusen Zhou, Guangyu Zhao
  • Patent number: 9803164
    Abstract: Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: October 31, 2017
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventor: Beau W. Mitchell
  • Patent number: 9724383
    Abstract: Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: August 8, 2017
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Zhi Qi, Xi Chen, Chungen Pan
  • Patent number: 9701736
    Abstract: Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: July 11, 2017
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Lanying Du, Yusen Zhou
  • Patent number: 9592287
    Abstract: Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: March 14, 2017
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Lanying Du
  • Patent number: 9574178
    Abstract: Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: February 21, 2017
    Assignee: New York Blood Center, Inc.
    Inventors: W. Beau Mitchell, Mauro P. Avanzi
  • Patent number: 9480786
    Abstract: Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: November 1, 2016
    Assignee: The New York Blood Center, Inc.
    Inventors: Christopher D. Hillyer, Beth H. Shaz
  • Patent number: 9394518
    Abstract: This disclosure provides methods for preparing both a red blood cell (RBC)-containing product and a platelet-containing product from a plurality of blood units. The method comprises leukoreducing a plurality of blood units, separating RBCs, platelets, and plasma from the units to form leukoreduced blood components, pooling the leukoreduced RBC components; pooling the leukoreduced platelet components, treating the pooled components to inactivate one or more pathogens, adding a storage solution to components, dividing the pooled leukoreduced RBCs into a plurality of RBC-containing product units, each having a uniform number of RBCs, and dividing the pooled leukoreduced platelets into a plurality of platelet-containing product units, each having a uniform number of platelets.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: July 19, 2016
    Assignee: The New York Blood Center, Inc.
    Inventors: Beth H. Shaz, Christopher D. Hillyer
  • Patent number: 9309237
    Abstract: Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: April 12, 2016
    Assignees: NEW YORK BLOOD CENTER, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • Patent number: 9255140
    Abstract: The present disclosure relates to a method for inducing an antigen-specific immune response to an antigen in a mammal in need thereof, or potentiating an immune response, by administering to the mammal an effective amount of an isolated Ov-ASP, or at least one subunit of Ov-ASP.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: February 9, 2016
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Patent number: 9052325
    Abstract: Systems and methods are provided for assessing the risk of hemolytic disease of the fetus or neonate, neonatal alloimmune thrombocytopenic purpura, or transfusion-associated lung injury in a patient or transfusion recipient.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 9, 2015
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventor: Gregory R. Halverson